Absci vs Denali Therapeutics
Free cash flow was −$94 million at Absci and −$422 million at Denali Therapeutics.
Side by side
| Absci | Denali Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $3M | $0M |
| Revenue growth | −38.2% | — |
| Revenue growth a year, last 5 years | −10.2% | — |
| Gross margin | — | — |
| Operating margin | −4,297.0% | — |
| Net margin | −4,113.7% | — |
| Free cash flow | −$94M | −$422M |
| Free cash flow margin | −3,358.3% | — |
| Return on capital | −162.8% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 24.1% | 5.0% |
| Last close | $8.45 | $18.74 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $933,174, sold $132,328 | sold $1.3 million |
| Piotroski F-score | 3 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AbsciDenali Therapeutics
Operating margin
Percent of revenue
AbsciDenali Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AbsciDenali Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Absci and Denali Therapeutics pages.